Abstract 779
Background
The prognosis of patients with inoperable lower esophageal cancers remains poor with only option being concurrent chemo-radiation. Among the various agents available, there is no study done focusing on TWISTT score and QOL in southern Indian population.
Methods
This is a single-centre, two arm, retrospective analysis evaluating 75 patients with histologically confirmed inoperable adenocarcinoma esophagus lower 1/3rd who are on definitive chemoradiation. The patients were administered IV cisplatin 40 mg/m2 weekly IV (n = 38) as per institutional protocol vs Capecitabine 800 mg/m2 PO (n = 37) twice a day along with radiotherapy of 6600-7000 cGy over 35 fractions. Patients were evaluated over response evaluation criteria in solid tumors (RECIST) criteria 12 weeks after the last cycle of chemotherapy as well as for TWISTT score and QOL.
Results
The median duration of follow up was 20 months. Objective Response Rate (ORR) was observed in 84.2% of the patients with patients in the Cisplatin arm vs 86.4% in Capecitabine arm. There are no differences in the complete response (CR) and partial response (PR) rates in the two arms. The median overall survival was 20.7 months (95% CI: 18.8-, 28.7) in cisplatin arm vs 22.7 months (95% CI: 20.2-, 30.2). The median TWISTT score in Cisplatin was 246 days vs 228 days for capecitabine. The median QOL was similar in both arms.
Conclusions
Capecitabine vs Cisplatin along with concurrent radiotherapy had similar overall response rates and progression free survival with similar TWISTT score and QOL and either can be used for concurrent therapy based on physician/ patient preferences.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
A. Goutham.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4125 - DUBLIN-3, a Stage IIIb/IV NSCLC Phase (Ph)3 Trial Comparing the Plinabulin (P)/Docetaxel(D) Combination with D Alone
Presenter: Ramon Mohanlal
Session: Poster Display session 1
Resources:
Abstract
3345 - Escalation plans and DNACPR discussions in the unwell oncology patient
Presenter: Raghad Elghadi
Session: Poster Display session 1
Resources:
Abstract
4165 - The Relation between the Symptom Burden of Hospitalized Patients with Incurable Cancer and the Quality-of-Life of Their Family Caregivers
Presenter: Eman Tawfik
Session: Poster Display session 1
Resources:
Abstract
1784 - Clinical predictors for analgesic response to radiotherapy in patients with painful bone metastases
Presenter: Ragnhild Habberstad
Session: Poster Display session 1
Resources:
Abstract
5323 - 30-Day Mortality in Palliative Radiotherapy
Presenter: Shing Fung Lee
Session: Poster Display session 1
Resources:
Abstract
3942 - The relationship between Naldemedine administration and the maximum dose of oral opioids
Presenter: Shinya Kajiura
Session: Poster Display session 1
Resources:
Abstract
3698 - Exposure to low energy amplitude modulated radiofrequency electromagnetic fields (EMF) is associated with rapid improvement in quality of life (QoL) status in patients with advanced hepatocellular carcinoma (HCC), using various analyses of EORTC-C30.
Presenter: Elizabeth Santana
Session: Poster Display session 1
Resources:
Abstract
3885 - Olanzapine Combined with 5-HT3 RA Plus Dexamethasone for Prevention and Treatment of Chemotherapy-Induced Nausea and Vomiting in High and Moderate Emetogenic Chemotherapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Presenter: Jian-Guo Zhou
Session: Poster Display session 1
Resources:
Abstract
5700 - Early Palliative care in advanced cancer, is it really effective?
Presenter: Raquel Gómez Bravo
Session: Poster Display session 1
Resources:
Abstract
5924 - Deprescribing Potentially Inappropriate Medication in Cancer Patients
Presenter: Simon Reuter
Session: Poster Display session 1
Resources:
Abstract